Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in patients (N = 702) with residual high fasting TG levels (≥200 and <500 mg/dL) despite having optimized low-density lipoprotein cholesterol (LDL-C) levels (≥40 and <100 mg/dL) on statin therapy. Among patients randomized to IPE (4 g/day or 2 g/day) or placebo, 514 (73%) had diabetes mellitus. METHODS: A post hoc subgroup analysis of the ANCHOR study was conducted to assess the effects of IPE on median placebo-adjusted percent change from baseline in efficacy end point parameters in 3 subgroups: total (all subjects with diabetes-overall median baseline glycosylated hemoglobin A₁c [A₁c] = 6.8%), better-controlled diabetes (below median baseline A1c), and less-controlled diabetes (above median baseline A1c). RESULTS: Baseline efficacy parameters were similar among all groups except high-sensitivity C-reactive protein (hsCRP), which was higher in the total and less-controlled diabetes groups. Compared with placebo, IPE 4 g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like particle cholesterol in all 3 diabetes groups, LDL-C in the total diabetes group, and hsCRP in the total and less-controlled diabetes groups. Decreases in hsCRP and Apo B were much greater in patients with less-controlled diabetes. There were no significant increases in fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin resistance in any group. CONCLUSION: IPE 4 g/day significantly improved lipid and lipid-related parameters without worsening glycemic control in patients with diabetes and mixed dyslipidemia, with possibly greater effects among those with less-controlled diabetes. TRIAL REGISTRATION: Clinicaltrials.gov Identifier NCT01047501.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
(1999) · PubMed · Cited by 2,062
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationBantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Body mass index, diabetes, and C-reactive protein among U.S. adults.
Ford, E. S. (1999) · Diabetes Care · doi:10.2337/diacare.22.12.1971 · Cited by 644
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Resnick, H. E., Foster, G. L., Bardsley, J., & Ratner, R. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1254 · Cited by 428
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Self-citationRobinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Self-citationOmega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-analysis
Wu, J. H. Y., Micha, R., Imamura, F., Pan, A., Biggs, M. L., Ajaz, O., Djousse, L., B. Hu, F., & Mozaffarian, D. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001602 · Cited by 340
n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review
Nettleton, J. A., & Katz, R. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.11.029 · Cited by 339
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284
Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus
Hartweg, J., Perera, R., Montori, V. M., Dinneen, S. F., Neil, A. H., & Farmer, A. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003205.pub2 · Cited by 282
Jacobson, T. A., Glickstein, S. B., Rowe, J. D., & Soni, P. N. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.10.018 · Cited by 263
Self-citationFruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Safety and efficacy of Omacor in severe hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199710000-00011 · Cited by 252
Statins and diabetes – Authors' reply
Kearney, P. M., Keech, A., Simes, J., Collins, R., & Baigent, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60761-8 · Cited by 185
Oikawa, S., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Sasaki, J., Hishida, H., Itakura, H., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.029 · Cited by 125
Hartweg, J., Farmer, A. A., Perera, R., Holman, R. R., & Neil, H. A. W. (2007) · Diabetologia · doi:10.1007/s00125-007-0695-z · Cited by 125
Kromhout, D., Geleijnse, J. M., de Goede, J., Oude Griep, L. M., Mulder, B. J. M., de Boer, M.-J., Deckers, J. W., Boersma, E., Zock, P. L., & Giltay, E. J. (2011) · Diabetes Care · doi:10.2337/dc11-0896 · Cited by 116
Trends in the Risk for Coronary Heart Disease Among Adults With Diagnosed Diabetes in the U.S.
Ford, E. S. (2011) · Diabetes Care · doi:10.2337/dc10-2251 · Cited by 105
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94
Self-citationDavidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.08.001 · Cited by 71
Self-citationHou, L., Lian, K., Yao, M., Shi, Y., Lu, X., Fang, L., He, T., & Jiang, L. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-126 · Cited by 46
Mocking, R. J. T., Assies, J., Bot, M., Jansen, E. H. J. M., Schene, A. H., & Pouwer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049431 · Cited by 39
Sasaki, J., Miwa, T., & Odawara, M. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0394 · Cited by 31
Marchioli, R., Marfisi, R. M., Borrelli, G., Chieffo, C., Franzosi, M. G., Levantesi, G., Maggioni, A. P., Nicolosi, G. L., Scarano, M., Silletta, M. G., et al. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/01.jcm.0000289271.80180.b6 · Cited by 30
McPherson, R. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.009 · Cited by 28
C-reactive protein: a marker or a player?
Nyström, T. (2007) · Clinical Science · doi:10.1042/cs20070121 · Cited by 28
Kazemian, P., Kazemi‐Bajestani, S. M. R., Alherbish, A., Steed, J., & Oudit, G. Y. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6397-x · Cited by 28
HDL and CETP Inhibition: Will This DEFINE the Future?
Davidson, M. H. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0191-8 · Cited by 13
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0223-y · Cited by 6
Research works printed but not linked: 2
- Manual of Laboratory Operations: LRC Program, Vol. 1: Lipid and Lipoprotein Analysis. DHEW Publication No. (NIH) 75-628. May 1974. Department of Health, Education, and Welfare: Washington, DC; 1982.
- McPherson R: Remnant cholesterol: "Non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. J Am Coll Cardiol 2013, 61:437-439.
Cited by
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Self-citationHypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-2085133501150912 · Cited by 186
Sakai, C., Ishida, M., Ohba, H., Yamashita, H., Uchida, H., Yoshizumi, M., & Ishida, T. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187934 · Cited by 179
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129
Metadata
- Authors
- Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N.
- Affiliations
- Foundation for Biomedical Research (US)
- Baylor College of Medicine (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Amarin (United States) (US)
- Corresponding author
- Brinton, Eliot A
- Venue
- Cardiovascular Diabetology
- Published
- 2013
- Volume
- 12
- Issue
- 1
- Pages
- 100
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC3718763
- OpenAlex
- W2134172530
- Cited by
- 70
- References
- 45
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 10 · 2019: 10 · 2018: 1 · 2017: 5 · 2016: 13 · 2015: 2 · 2014: 6
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Cargill
- Gilead Sciences
- Amarin Corporation
- Kowa Company
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Shionogi
- Esperion Therapeutics
- National Institutes of Health
- Genentech
- Amarin Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- icosapent ethyl, eicosapentaenoic acid, hypertriglyceridemia, type 2 diabetes, statin therapy, LDL cholesterol, triglycerides, high-sensitivity C-reactive protein, apolipoprotein B, lipoprotein-associated phospholipase A2, remnant-like particle cholesterol, oxidized LDL, glycemic control
- MeSH terms
- Hypolipidemic Agents, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Time Factors, Triglycerides, Eicosapentaenoic Acid, Biomarkers, Treatment Outcome, Inflammation Mediators, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.